Abstract 313P
Background
Quantitative analyses of miRNA are potential methods for the detection of carcinoma. Some studies have revealed the importance of microRNAs (miRNAs) function as biomarkers in diagnosing renal cell carcinoma. However, some results are discordant. This study is the first to systematically evaluate the accuracy of circulating miRNA for the diagnosis of renal cell carcinoma found in plasma, serum and urine by conducting meta-analysis.
Methods
We searched PubMed, Embase, Cochrane Library and Google Scholar databases systematically for relevant literatures up to January 10, 2020. The HSROC model was used to calculate the pooled diagnostic parameters and summary receiver operator characteristic (SROC) curve in this meta-analysis, thereby estimating the whole predictive performance. Meta-regression was performed to identify the sources of heterogeneity. All analyses were conducted using RevMan 5.3, MetaDTA, Metadisc Ver 3.0 and Medcalc Ver 19.
Results
This meta-analysis included a total of 18 studies in 12 researches, including 817 renal cell carcinoma patients and 622 healthy controls. The summary estimates for quantitative analysis of miRNA in renal cell carcinoma were as follows: sensitivity, 0.80 (95% confidence interval (CI), 0.75– 0.83); specificity, 0.69 (95% CI, 0.61–0.76); positive likelihood ratio, 2.6 (95% CI, 2.0– 3.2); negative likelihood ratio, 0.28 (95% CI, 0.22–0.34); diagnostic odds ratio, 9.2 (95% CI, 5.7–12.8); and area under the curve, 0.74 (95% CI, 0.70–0.78). Additionally, sub-group and meta-regression analyses revealed that there were no significant differences between ethnicity, year of publication, sample type and miRNA profiling. There was no statistical significance for the evaluation of publication bias.
Conclusions
Current evidence suggests that quantitative analysis of miRNA has acceptable sensitivity but unsatisfactory specificity for the diagnosis of renal cell carcinoma. Further large-scale prospective studies are required to validate the potential applicability of using miRNA alone or in combination with diagnostic test for renal cell carcinoma and explore potential factors that may influence the accuracy of renal cell carcinoma diagnosis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jestoni V. Aranilla MD.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
253P - Non-Epithelial Tumours of Ovary, An Experience from Qatar
Presenter: Ammar Madani
Session: e-Poster Display Session
260P - A phase I study of copanlisib, a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor, in Chinese patients with relapsed indolent non-Hodgkin lymphoma (iNHL)
Presenter: Yuqin Song
Session: e-Poster Display Session
261P - Clinical outcomes of early-progressed follicular lymphoma in Korea: A multicenter, retrospective analysis
Presenter: Jun Ho Yi
Session: e-Poster Display Session
262P - Correlation between phosphorylated pI3K expression, phosphorylated AKT, and phosphorylated MTOR with serum dehydrogenase lactate level in non-Hodgkin lymphoma
Presenter: Hary Gustian
Session: e-Poster Display Session
263P - Good response to chemotherapy in primary CNS lymphoma may not translate into significant neurocognitive improvement in comatose patients
Presenter: Ryan Lim
Session: e-Poster Display Session
264P - Treatment outcome of primary testicular lymphoma patients treated in tertiary care centre in Chennai
Presenter: Sivasubramaniam Kumaravelu
Session: e-Poster Display Session
271P - Cost-effectiveness of pembrolizumab as monotherapy or in combination with chemotherapy versus EXTREME regimen for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in Taiwan
Presenter: Cheng Hsu Wang
Session: e-Poster Display Session
272P - Early metabolic changes in PET metrics over initial 8 weeks of treatment in patients with advanced head neck squamous cell carcinomas treated with chemotherapy
Presenter: Ashish Vaidya
Session: e-Poster Display Session
273P - Long term outcomes of locally advanced & borderline resectable esthesioneuroblastoma and sinonasal tumour with neuroendocrine differentiation treated with neoadjuvant chemotherapy
Presenter: Vikas Talreja
Session: e-Poster Display Session
274P - Comparing comorbidity indices in predicting 90-day mortality after radical radiotherapy for head and neck cancer
Presenter: Therese Tsui
Session: e-Poster Display Session